Table 1.
Patient characteristics.
| Characteristic | Discovery | Validation | Controls |
|---|---|---|---|
| n | 11 | 11 | 30 |
| Ethnicity | Asian | Asian | Asian |
| Age | 58 (40–76) | 63 (27–68) | 45 (40–64) |
| FIGO stage | |||
| I | 0 (0.0%) | 1 (9.1%) | |
| II | 3 (27.3%) | 2 (18.2%) | |
| III | 6 (54.5%) | 8 (72.7%) | |
| IVA | 2 (18.2%) | 0 (0.0%) | |
| Tumor volume* | |||
| ≤30 cm3 | 5 (45.4%) | 4 (36.4%) | |
| 31–100 cm3 | 4 (36.4%) | 6 (54.5%) | |
| >100 cm3 | 2 (18.2%) | 1 (9.1%) | |
| Pelvic LN involvement | |||
| Negative | 4 (36.4%) | 5 (45.4%) | |
| Positive | 7 (63.6%) | 6 (54.5%) | |
| PALN involvement | |||
| Negative | 10 (90.9%) | 8 (72.7%) | |
| Positive | 1 (9.1%) | 3 (27.3%) | |
| Concurrent chemotherapy | |||
| Yes | 9 (81.8%) | 10 (90.9%) | |
| No | 2 (18.2%) | 1 (9.1%) | |
Controls, ethnicity- and sex-matched non-cancer subjects; Discovery, discovery cohort; FIGO, the International Federation of Gynecology and Obstetrics 2009; LN, lymph node; PALN, para-aortic lymph node; Validation, validation cohort. Age is shown as the median (range). *based on T2-weighted magnetic resonance images.